85 related articles for article (PubMed ID: 36831254)
1. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.
Tang H; Miao X; Yu C; Chai C; Su Y; Li L; Yi J; Ye Z; Miao L; Wang Z; Zhang H; Xu H; Zhou W
Sci Rep; 2024 Apr; 14(1):9259. PubMed ID: 38649719
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence-based analysis of time-lapse images of sphere formation and process of plate adhesion and spread of pancreatic cancer cells.
Shichi Y; Gomi F; Hasegawa Y; Nonaka K; Shinji S; Takahashi K; Ishiwata T
Front Cell Dev Biol; 2023; 11():1290753. PubMed ID: 38046666
[No Abstract] [Full Text] [Related]
3. Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.
Xu H; Chai CP; Tang H; Su YH; Yu C; Li L; Yi JF; Ye ZZ; Wang ZF; Hu JJ; Luo W; Zhang H; Miao X; Zhou WC
World J Oncol; 2024 Feb; 15(1):114-125. PubMed ID: 38274721
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of DPC-X4: a novel mixed-type ampullary cancer cell line.
Chai C; Tang H; Yi J; Li L; Yu C; Su Y; Miao L; Ye Z; Wang Z; Luo W; Hu J; Zhang H; Miao X; Xu H; Zhou W
Hum Cell; 2024 Mar; 37(2):531-545. PubMed ID: 38253956
[TBL] [Abstract][Full Text] [Related]
5. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations.
Färber B; Lapshyna O; Künstner A; Kohl M; Sauer T; Bichmann K; Heckelmann B; Watzelt J; Honselmann K; Bolm L; Ten Winkel M; Busch H; Ungefroren H; Keck T; Gemoll T; Wellner UF; Braun R
Front Oncol; 2023; 13():1230382. PubMed ID: 37719017
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
7. Treatment landscape of metastatic pancreatic cancer.
De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
[TBL] [Abstract][Full Text] [Related]
8. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract][Full Text] [Related]
9. Rac1b negatively regulates TGF-β1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling.
Ungefroren H; Sebens S; Giehl K; Helm O; Groth S; Fändrich F; Röcken C; Sipos B; Lehnert H; Gieseler F
Oncotarget; 2014 Jan; 5(1):277-90. PubMed ID: 24378395
[TBL] [Abstract][Full Text] [Related]
10. The Crosstalk between Nrf2 and TGF-β1 in the Epithelial-Mesenchymal Transition of Pancreatic Duct Epithelial Cells.
Arfmann-Knübel S; Struck B; Genrich G; Helm O; Sipos B; Sebens S; Schäfer H
PLoS One; 2015; 10(7):e0132978. PubMed ID: 26226105
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRINOX
Begg SKS; Birnbaum DJ; Clark JW; Mino-Kenudson M; Wellner UF; Schilling O; Lillemoe KD; Warshaw AL; Castillo CF; Liss AS
Anticancer Res; 2020 Jul; 40(7):3659-3667. PubMed ID: 32620605
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition via transforming growth factor beta in pancreatic cancer is potentiated by the inflammatory glycoprotein leucine-rich alpha-2 glycoprotein.
Otsuru T; Kobayashi S; Wada H; Takahashi T; Gotoh K; Iwagami Y; Yamada D; Noda T; Asaoka T; Serada S; Fujimoto M; Eguchi H; Mori M; Doki Y; Naka T
Cancer Sci; 2019 Mar; 110(3):985-996. PubMed ID: 30575211
[TBL] [Abstract][Full Text] [Related]
14. The Quasimesenchymal Pancreatic Ductal Epithelial Cell Line PANC-1-A Useful Model to Study Clonal Heterogeneity and EMT Subtype Shifting.
Ungefroren H; Thürling I; Färber B; Kowalke T; Fischer T; De Assis LVM; Braun R; Castven D; Oster H; Konukiewitz B; Wellner UF; Lehnert H; Marquardt JU
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565186
[TBL] [Abstract][Full Text] [Related]
15. Activation of a Ductal-to-Endocrine Transdifferentiation Transcriptional Program in the Pancreatic Cancer Cell Line PANC-1 Is Controlled by RAC1 and RAC1b through Antagonistic Regulation of Stemness Factors.
Schmidtlein PM; Volz C; Hackel A; Thürling I; Castven D; Braun R; Wellner UF; Konukiewitz B; Riemekasten G; Lehnert H; Marquardt JU; Ungefroren H
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771704
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
